In-vitro activity of Sch 34343, a new penam, against gram-positive isolates from cancer patients.
The in-vitro activity of Sch 34343, a new penam antibiotic, was tested against 257 Gram-positive isolates from cancer patients, and compared with that of imipenem and amifloxacin. Sch 34343 was extremely active against beta-haemolytic streptococci (Lancefield groups A, B and G) with MIC90s ranging from 0.025 to 0.05 mg/l. It was also active against methicillin-susceptible Staphylococcus aureus and had variable activity against coagulase-negative staphylococci. MIC90 for Listeria monocytogenes was 0.78 mg/l and 84% of enterococcal isolates were inhibited by 6.25 mg/l.
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D000890:Anti-Infective Agents; D001424:Bacterial Infections / Q000150:complications / Q000382:microbiology*; D002939:Ciprofloxacin / Q000031:analogs & derivatives / Q000494:pharmacology; D024841:Fluoroquinolones; D006094:Gram-Positive Bacteria / Q000187:drug effects*; D006801:Humans; D015378:Imipenem; D007769:Lactams; D008089:Listeria monocytogenes / Q000187:drug effects; D009369:Neoplasms / Q000150:complications*; D013210:Staphylococcus / Q000187:drug effects; D013291:Streptococcus / Q000187:drug effects; D013845:Thienamycins / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D007769:Lactams; D013845:Thienamycins; D002939:Ciprofloxacin; C040691:amifloxacin; D015378:Imipenem; C044617:Sch 34343